

## CURRICULUM VITAE

NAME: **David M. Labiner**

CITIZENSHIP: United States

PERSONAL: Married, two children

CURRENT POSITION: Department Head, Department of Neurology  
Professor of Neurology (with tenure), College of Medicine  
Professor of Pharmacy Practice and Science, College of Pharmacy  
The University of Arizona Health Sciences Center  
1501 North Campbell Avenue  
Tucson, Arizona 85724

TELEPHONE: 520-626-2006

EDUCATION:

Undergraduate: Emory University, Atlanta, Georgia 30322  
March 1979 - B.A., Psychology,  
Magna cum laude

Graduate: Medical College of Georgia  
Augusta, Georgia 30912  
June 1984 - M.D.

INTERNSHIP: Department of Internal Medicine  
Medical College of Georgia  
Augusta, Georgia 30912  
1 July 1984 to 30 June 1985

RESIDENCY: Department of Neurology  
College of Physicians and Surgeons  
Columbia University  
The Neurological Institute of New York  
710 West 168th Street  
New York, New York 10032  
1 July 1985 to 30 June 1988

FELLOWSHIP:

Duke Center for the Advanced Study  
of Epilepsy  
Duke University Medical Center  
Department of Medicine (Neurology)  
Durham, North Carolina 27710  
1 July 1988 to 30 June 1989

APPOINTMENTS:

Associate in Medicine (Neurology)  
Duke University Medical Center  
Durham, North Carolina  
1 July 1989 - 30 June 1991

Director, Arizona Comprehensive Epilepsy Program  
Assistant Professor  
University of Arizona College of Medicine  
Department of Neurology  
Tucson, Arizona  
1 July 1991 – 30 June 1998

Clinical Instructor  
University of Arizona College of Pharmacy  
Department of Pharmacy Practice  
Tucson, Arizona  
19 January 1996 – 30 June 1998

Associate Professor of Neurology (with tenure) and Clinical  
Associate Professor of Pharmacy Practice and Science,  
Colleges of Medicine and Pharmacy  
The University of Arizona Health Science Center  
Tucson, Arizona  
1 July 1998 – 30 June 2004

Associate Department Head, Department of Neurology  
The University of Arizona Health Sciences Center  
1501 North Campbell Avenue  
Tucson, Arizona 85724  
1 July 1998 – 24 September 2008

Department Head (Interim), Department of Neurology  
The University of Arizona Health Sciences Center  
1501 North Campbell Avenue  
Tucson, Arizona 85724  
24 September 2008 – 22 February 2010

CLINICAL APPOINTMENTS:

Staff Physician  
Department of Medicine (Neurology)  
Veterans Administration Medical Center  
Durham, North Carolina  
1 August 1989 - 30 June 1991

Staff Physician, Department of Neurology  
Department of Veterans Affairs Medical Center  
Tucson, Arizona  
29 October 1991 - present

Courtesy Staff  
Yuma Regional Medical Center  
Yuma, Arizona  
2 April 1992 - present

Staff Physician, Tucson Medical Center  
Tucson, Arizona  
11 January 1994 - present

Consultant, Kindred Hospital of Tucson  
Tucson, Arizona  
28 November 1994 - present

Consultant, Indian Health Service  
Chinle, Kayenta, Tuba City, Polacca, Winslow, Arizona  
15 January 1996 - present

LICENSURE:

New York State - Physician # 162660 (inactive), 1 July 1985  
North Carolina - Physician # 32388 (inactive), 7 May 1988  
Arizona - Physician # 20248, 19 August 1991  
Drug Enforcement Administration # AL 3284065

CERTIFICATION:

National Board of Medical Examiners, #291923, July 1985  
American Board of Psychiatry and Neurology, #35363, January 1992

HONORS AND AWARDS:

Psi Chi, 1977  
Mortar Board, 1978  
Omicron Delta Kappa, 1978  
Who's Who in American Universities and  
Colleges, 1978  
B.A., Magna cum laude, 1979  
Dean's Student Research Fellow, 1981  
Alpha Omega Alpha, 1983  
Sandoz Research Award, 1984  
Clinical Neurosciences Award, 1984  
AMA Physician Recognition Award, 1987-1990  
AMA Physician Recognition Award, 1990-1993  
University Medical Center - *Patient's Choice Award*,  
1992  
AMA Physician Recognition Award, 1993-1996  
Epilepsy Society of Arizona - *Volunteer of the Year*,  
1993  
*Best Doctors in America* - Pacific Region, 1996  
AMA Physician Recognition Award, 1996-1999  
Who's Who in Science and Engineering, 1997  
*Best Doctors in America*, 1998  
Arizona Achievement Awards, 1999 – Governor's Council  
on Developmental Disabilities  
University of Arizona College of Medicine – *Best  
Contributions in Continuing Medical Education*,  
1999  
Who's Who in America, 2000  
Who's Who in Science and Engineering, Millennium Edition  
Who's Who in America, 2001  
Who's Who in America, 2002  
Who's Who in Science and Engineering 2002 – 2003  
Fellow, Royal Society of Medicine, 2001  
Life Member, National Registry Kingston Who's Who, 2002  
*Best Doctors in America*, 2002  
Who's Who in Medicine and Healthcare, 2002 – 2003  
Candle of Light Award, Epilepsy Foundation - Arizona, 2003  
Volunteer of the Year (national), Epilepsy Foundation, 2003  
*Best Doctors in America*, 2003-2004  
University Medical Center and University Physicians  
*Patient's Choice Award*, honorable mention, 2003  
Department of Neurology, *Educator of the Year*, 2005  
*Best Doctors in America*, 2005-2006  
*Best Doctors in America*, 2007-2008  
*Best Doctors in America*, 2009-2010  
*Campbell – Wyeth Award for Best Research in Continuing  
Medical Education*, Alliance for CME, 2008

CURRENT SERVICE:

University: College of Medicine - Clinical Advisor

University Medical Center:

Arizona Comprehensive Epilepsy Program, Director  
Bioethics Committee  
Board of Directors (Medical staff representative)  
Quality Care Committee  
Medical Executive Committee

Community:

Epilepsy Foundation of Arizona  
Board of Directors (1992 - present)  
President (1998 – 2001)

Professional:

National Association of Epilepsy Centers  
Board of Directors, 1998 – present  
Vice President, 2000 – 2003, 2011 - present  
Secretary/Treasurer 2004 – 2010  
American Epilepsy Society  
Scientific Program Committee, 1998 – 1999  
Continuing Medical Education Committee, 2000 – 2003  
Annual Meeting Committee, 2003 – 2009  
Chairman, 2006 – 2009  
Council on Education, 2006 – present  
Chairman, 2009 – present  
International League Against Epilepsy  
Commission on Education, 2009 - present  
Epilepsy Foundation (national)  
Professional Advisory Board (2004 – present)  
Board of Directors (2006 – present)  
American Academy of Neurology  
Medical Student Essay Awards Subcommittee, 2005 – 2010  
Chairman, 2011 – present  
Councilor, Epilepsy Section, 2009 - 2011  
Center for Disease Control and Prevention  
Ad hoc committee for Standards for Epidemiologic Studies and  
Surveillance of Epilepsy, 2007

PREVIOUS SERVICE:

University: College of Medicine - Administrative Review Committee of the  
Department Head of Neurology, Chairman  
College of Medicine - Preparation for Clinical Medicine Course  
Review Subcommittee  
University of Arizona - Upper-Division Writing Proficiency Exam  
Grader  
College of Medicine - Medical School Interviewer  
University of Arizona - Honors thesis advisor - Todd MacGregor,  
Undergraduate student, 1994-1995  
College of Medicine - Student Progress Committee  
University of Arizona - Masters thesis advisor - Amy N. Grudzinski,  
Graduate Student, Department of Pharmacy Practice, 1996-97  
College of Medicine – Residency Downsizing Committee, 1996, 1997  
University of Arizona – Academic Program Review Committee for the  
Department of Ophthalmology, 2000  
College of Medicine – Academic Program Review, Department of Neurology, Chairman  
College of Medicine – Administrative Review of Dr. Bruce Coull, Chairman  
Department of Neurology  
Department of Neurology Residency Training Program Director, 1994 - 2009  
College of Medicine - Graduate Medical Education Committee, 1994 – 2009  
(Chair, 1998 – 2000)  
Neurophysiology Fellowship Supervisor for Darry Johnson, M.D.  
and Maura Kolb, D.O., 1995-1996  
Epilepsy/Electroencephalography Fellowship Supervisor for Scott  
Sherman, M.D., Ph.D., 1996-1997  
Preceptor for Scott Sherman, M.D., Ph.D., Fellowship Grant from the  
American Epilepsy Society, 1996-1997  
University of Arizona - Ph.D. Committee – Sheryl Reminger, Department of  
Psychology, 2001  
Epilepsy/Electroencephalography Fellowship Supervisor for Hemant  
Kudrimoti, M.D., Ph.D., 2003-2004  
Epilepsy/Electroencephalography Fellowship Supervisor for Myrka R.  
Torres, M.D., 2004-2005  
College of Medicine – Continuing Medical Education Committee (Vice-  
Chair, 2002 – 2005)  
College of Medicine - Neuroscience Standing Oversight Subcommittee  
University of Arizona - Ph.D. Committee – Sharon Antonucci, Department  
of Speech, Language and Hearing Sciences, 2005  
Epilepsy/Electroencephalography Fellowship Supervisor for Keith O.  
Gonzalez, M.D., 2005-2006  
College of Medicine – Admissions Committee, 2003 – 2006  
Epilepsy/Electroencephalography Fellowship Supervisor for Eric J. Foltz,  
M.D., 2006–2007  
Epilepsy/Electroencephalography Fellowship Supervisor for Paul B.  
Atkinson, M.D., 2007–2008

PREVIOUS SERVICE (continued):

Epilepsy/Electroencephalography Fellowship Supervisor for Jimmy Nguyen,  
M.D., 2008 – 2009

Epilepsy/Electroencephalography Fellowship Supervisor for Kendra Drake,  
M.D., 2009 – 2010

University Medical Center:

Credentials Committee

Arizona Comprehensive Epilepsy Program - Professional Advisory Committee  
Case Review Committee

Professional

American Epilepsy Society - Scientific Program Committee, 1998 – 1999

National Association of Epilepsy Centers - Chairman, Nominating Committee, 1997

American Academy of Neurology:

Practice Committee - Quality Standards Subcommittee

Ad hoc Committee on Pregnancy and Epilepsy

Epilepsy Foundation – Centers for Disease Control

Living Well with Epilepsy II Conference,

Planning Committee, 2002 -2003

Community:

Cimarron Foothills Community Association Board of Directors

Arizona Department of Motor Vehicles

Ad hoc Committee on Driving and Epilepsy

Epilepsy Society of Arizona

Professional Advisory Board, Chairman (1992-1996)

President-elect (1997-1998)

State of Arizona, Department of Developmental Disabilities

Ad hoc advisor regarding eligibility criteria for epilepsy (2003-2004)

## PUBLICATIONS:

1. Smith DB, Sidman RD, Henke JS, Flanigin HF, Labiner DM, Evans CN. Scalp and depth recordings of induced deep cerebral potentials. *Electroencephalography and Clinical Neurophysiology* **55**: 145-150, 1983.
2. Smith DB, Sidman RD, Flanigin HF, Henke JS, Labiner DM. A reliable method for localizing deep intracranial sources of the EEG. *Neurology* **35**: 1702-1707, 1985.
3. Simonato MG, Hosford DA, Labiner DM, Shin C, Mansbach HH, McNamara JO. Differential expression of immediate early genes in the hippocampus in the kindling model of epilepsy. *Molecular Brain Research* **11**: 115-124, 1991.
4. Sorock GS, Labiner DM. Peripheral neuromuscular dysfunction and the risk of falling in the elderly. *American Journal of Epidemiology* **136**: 584-591, 1992.
5. Labiner DM, Butler LS, Cao Z, Hosford DA, Shin C, McNamara JO. Induction of c-fos mRNA by kindled seizures: Lack of correlation with neuronal burst firing. *The Journal of Neuroscience* **13**: 744-751, 1993.
6. Ahern GL, Herring AM, Tackenberg J, Seeger JF, Oommen KJ, Labiner DM, Weinand ME. The association of multiple personality and temporolimbic epilepsy: Intracarotid amobarbital test observations. *Archives of Neurology* **50**: 1020-1025, 1993.
7. Ahern GL, Herring AM, Tackenberg JN, Schwartz GE, Seeger JF, Labiner DM, Weinand ME, Oommen KJ. Affective self-report during the intracarotid sodium amobarbital test. *Journal of Experimental and Clinical Neuropsychology* **16**: 372-376, 1994.
8. Weinand ME, Hermann BP, Wyler AR, Carter LP, Oommen KJ, Labiner DM, Ahern GL, Herring AM. Long-term subdural strip electrocorticographic monitoring of ictal déjà vu. *Epilepsia* **35**: 1054-1059, 1994.
9. Llewellyn PL, Labiner DM, Weinand ME, Huxtable RJ. Neuroactive amino acids in synaptosomes from focal and nonfocal temporal lobe tissue of patients with intractable complex partial seizures. *Advances in Experimental Medicine and Biology* **359**: 435-444, 1994.
10. Ahern GL, Labiner DM, Hutzler R, Osburn C, Talwar D, Herring AM, Tackenberg JN, Oommen KJ, Weinand ME. Quantitative analysis of the EEG in the intracarotid amobarbital test: I. Amplitude analysis. *Electroencephalography and Clinical Neurophysiology* **91**: 21-32, 1994.
11. Weinand ME, Carter LP, Patton DD, Oommen KJ, Labiner DM, Talwar D. Long-term surface cortical cerebral blood flow monitoring in temporal lobe epilepsy. *Neurosurgery* **35**: 664, 1994.
12. Ahern GL, Labiner DM, Talwar D, Herring AM, Tackenberg J, Weinand ME, Oommen KJ. Quantitative analysis of the EEG in the intracarotid amobarbital test: II. Coherence analysis. *Journal of Clinical Neurophysiology* **12**: 285-290, 1995.
13. Weinand ME, El-Saadany WF, Carter LP, Labiner DM, Oommen KJ, Talwar D, Ahern GL. Temporal lobe ischemia and epileptogenicity: Long-term cortical cerebral blood flow analysis of sequential seizures. *Surgical Forum* **46**: 574-575, 1995.
14. Weinand ME, Carter LP, Oommen KJ, Hutzler R, Labiner DM, Talwar D, El-Saadany WF, Ahern GL. Response of human epileptic temporal lobe cortical blood flow to hyperventilation. *Epilepsy Research* **21**: 221-226, 1995.
15. Devinsky O and the Intravenous Valproate Study Team. Safety of intravenous valproate. *Annals of Neurology* **38**: 670-674, 1995.
16. Weinand ME, El-Saadany W, Labiner DM, Talwar D, Ahern G. Subdural strip electrode monitoring and surgical decision making in refractory epilepsy: Validity and prognostic value of noninvasive localizing data. *Journal of Epilepsy* **8**: 131-138, 1995.
17. Labiner DM. Vagal nerve stimulation - A new paradigm for treating epilepsy. *Clinical Research News for Arizona Physicians* **7**: 1, 1996.



18. Labiner DM. New anti-epileptic medications: new hope for individuals with seizures. *Clinical Research News for Arizona Physicians* **7**: 2, 1996.
19. Weinand ME, El-Saadany W, Labiner DM, Carter LP, Oommen KJ, Talwar D, Ahern G. Abnormal vasomotor response of human epileptogenic cortex to reversal of hyperventilation: A long-term surface cerebral blood flow monitoring study. *Pathophysiology* **3**: 41-45, 1996.
20. Weinand ME, Carter LP, El-Saadany WF, Sioutos PJ, Labiner DM, Oommen KJ. Cerebral blood flow and temporal lobe epileptogenicity. *Neurosurgical Focus*, "Epilepsy", November, 1996 (NEUROSURGERY://ON-CALL web site at <http://www.aans.org>).
21. Weinand ME, Carter LP, El-Saadany WF, Sioutos PJ, Labiner DM, Oommen KJ. Cerebral blood flow and temporal lobe epileptogenicity. *Journal of Neurosurgery* **86**: 226-232, 1997.
22. Ahern GL, Herring AM, Labiner DM, Weinand ME. Quantitative analysis of hemispatial neglect in the intracarotid sodium amobarbital test. *Journal of the International Neuropsychological Society* **4**: 99-105, 1998.
23. Semenchuk MR, Labiner DM. Gabapentin and Lamotrigine: Guidelines for psychiatry. *Journal of Practical Psychiatry and Behavioral Health* **3**: 334-342, 1997.
24. Grudzinski AN, Hakim Z, Coons SJ, Labiner DM. An assessment of the usefulness of the QOLIE-31 in routine clinical practice. *Journal of Epilepsy* **11**: 34 - 47, 1998.
25. Handforth A, and the E05 Study Team. Vagus nerve stimulation therapy for partial onset seizures. *Neurology* **51**: 48-55, 1998.
26. Zahn CA, Morrell MJ, Collins SD, Labiner DM, Yerby MS. Management issues for women with epilepsy: A review of the literature. *Neurology* **51**: 949-956, 1998.
27. Griffiths RI, Schrammel PN, Morris GL, Wills SH, Labiner DM, Strauss MJ. Payer costs of patients diagnosed with epilepsy. *Epilepsia* **40**: 351-358, 1999.
28. Zahn CA, Morrell MJ, Collins SD, Labiner DM, Yerby MS. Management issues for women with epilepsy. (Correspondence). *Neurology* **53**: 656, 1999.
29. Murphy JV and the Pediatric VNS Study Group. Left vagal nerve stimulation: Experience in 60 children with pharmacoresistant epilepsy. *Journal of Pediatrics* **134**: 563-566, 1999.
30. Labiner DM. Data v. opinion, phenytoin versus fosphenytoin: The saga continues. *Archives of Internal Medicine* **159**: 2631-2632, 1999.
31. Weinand ME, Takacs I, Ahern GL, Labiner DM. Nonepileptic cortical cerebral blood flow and temporal lobe epileptogenicity. *Pathophysiology* **6**: 135-141, 1999.
32. Morris GL III and the Vagus Nerve Stimulation Study Group. Long-term treatment with vagus nerve stimulation in refractory epilepsy patients. *Neurology* **53**: 1731-1735, 1999.
33. Labiner DM, Yan CC, Weinand ME, Huxtable RJ. Disturbances of amino acids from temporal lobe synaptosomes in human complex partial epilepsy. *Neurochemical Research* **24**: 1379-1383, 1999.
34. Rapcsak SZ, Galper SR, Comer JF, Reminger MA, Nielsen L, Kaszniak AW, Verfaellie M, Laguna JF, Labiner DM, Cohen RA. The perception of fear: a cautionary note. *Neurology* **54**: 575-581, 2000.
35. Sirven JI and the Vagus Nerve Stimulation Study Group. Vagus nerve stimulation therapy for epilepsy in older adults. *Neurology* **54**: 1179-1182, 2000.
36. Grudzinski AN, Hakim Z, Labiner DM, Cox ER, Bootman JL. An economic assessment of the relationship between disease exacerbations and the cost of multiple sclerosis to a managed care organization. *Journal of Managed Care Pharmacy* **6**: 19-24, 2000.
37. Ahern GL, Herring AM, Weinand ME, Hutzler R, Labiner DM. Affective self-report during the ISA: Group differences. *Journal of International Neuropsychological Society* **6**: 659-667, 2000.
38. Weinand ME, Deogaonkar M, Kester M, Ahern GL, Labiner DM. Electrographic factors associated with temporal lobe epileptogenicity. *Pathophysiology* **7**: 33-39, 2000.

39. DeGiorgio CM and VNS Study Group. Prospective long-term study of vagus nerve stimulation for the treatment of refractory partial seizures. *Epilepsia* **41**: 1195-1200, 2000.
40. Dasheiff RM and VNS Study Group. Vagal nerve stimulation does not unkindle seizures. *Journal of Clinical Neurophysiology* **18**: 68 – 74, 2001.
41. Ahern GL, Sollers J, Lane RD, Labiner DM, Herring AM, Weinand ME, Hutzler R, Thayer J. Heart rate and heart rate variability changes in the intracarotid sodium amobarbital (ISA) test. *Epilepsia* **42**: 912-921, 2001.
42. Weinand ME, Labiner DM, Ahern GL. Temporal lobe seizure interhemispheric propagation time depends on nonepileptic cortical cerebral blood flow. *Epilepsy Research* **44**: 33-39, 2001.
43. Weinand ME, Kester MM, Labiner DM, Ahern GL. Time from ictal subdural EEG seizure onset to clinical seizure onset: Prognostic value for selecting temporal lobectomy candidates. *Neurological Research* **23**: 599-604, 2001.
44. Walczak TS and the Committee to Revise the Guidelines for Specialized Epilepsy Centers. Guidelines for essential services, personnel, and facilities in specialized epilepsy centers. *Epilepsia* **42**: 804-814, 2001.
45. Skaff PT, Labiner DM. Status epilepticus due to human parvovirus B19 encephalitis in an immunocompetent adult. *Neurology* **57**: 1336-1337, 2001.
46. Weinand ME, Labiner DM, Ahern GL. Integration of perceptual and mnemonic dysfunction: Sensory auras are associated with left hemisphere memory dysfunction. *Epilepsy and Behavior* **2**: 423 – 432, 2001.
47. Labiner DM and Ahern GL. Neurologic consultation for seizures: When, why and how to pursue. *Postgraduate Medicine* **111**:53-64, 2002.
48. Labiner DM. The Centers for Disease Control and Prevention and its epilepsy initiative. *The Ictal Zone* **4**: 2 (Newsletter of the AAN Epilepsy Section), 2002.
49. Labiner DM. Alternative medicine and the treatment of epilepsy (letter). *Epilepsy and Behavior* **3**: 200-201, 2002.
50. Labiner DM. An evaluation of SPD-421 (DP-VPA) in the treatment of epilepsy. *Current Opinion in Investigational Drugs* **3**: 921 - 923, 2002.
51. Labiner DM. Lamotrigine and rash: scratching beneath the surface. *Journal of Clinical Psychiatry* **63**: 1010, 2002.
52. Labiner DM, Weinand ME, Ahern GL, Herring AM. Prognostic value of concordant seizure focus localizing data in the selection of temporal lobectomy candidates. *Neurological Research* **24**: 747 – 755, 2002.
53. Labiner DM. Treating refractory disease. In, Labiner DM, Benbadis SR, Wilner AA. Current management of epilepsy. The Virtual Lecture Hall (On-line CME). <http://www.vlh.com>. 2003 (updated 2006)
54. Drazkowski JF, Fisher RS, Sirven JI, Uber-Zak L, Hentz J, Labiner DM. Seizure related crashes in Arizona before and after shortening the driving restriction from 12 to 3 months. *Mayo Clinic Proceedings* **78**: 819 – 825, 2003.
55. Skaff PT, Labiner DM. Human parvovirus B19: a rare cause of adult encephalitis and status epilepticus. *Infectious Diseases: review series* **3**: 14 - 16, 2003.
56. Labiner DM. Neuronal substrates of sleep and epilepsy. (Book review). *Sleep* **27**: 2004.
57. Gonzalez-Portillo G, Rivero S, Ahern GL, Labiner DM, Weinand ME. Normalization of periictal bihemispheric cerebral perfusion in temporal lobe epilepsy. *Pathophysiology* **11**: 31 – 34, 2004.
58. Reminger SL, Kaszniak AW, Labiner DM, Littrell LD, David BT, Ryan L, Herring AM, Kaemingk KL. Bilateral hippocampal volume predicts verbal memory function in temporal lobe epilepsy. *Epilepsy and Behavior* **5**: 687-695, 2004.

59. Labiner DM. Current management of epilepsy: Primary Care Edition. The Virtual Lecture Hall (On-line CME). <http://www.vlh.com>, 2004 (updated 2006)
60. Carpenter LL, Moreno FA, Kling MA, Anderson GM, Regenold WT, Labiner DM, Price LH. Effect of vagus nerve stimulation on CSF monoamine metabolites, norepinephrine, and GABA concentrations in depressed patients. *Biological Psychiatry* **56**: 418 – 426, 2004.
61. Torres MR, Ahern GL, Labiner DM. Seizures and epilepsy: an approach to diagnosis and management. *Journal of Clinical Outcomes -Management* 12(2): 103-115, 2005.
62. Beydoun A and the Pregabalin 1008-009 Study Group. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. *Neurology* **64**: 475-480, 2005.
63. Meador KJ and the NEAD Study Team. *In utero* drug exposure: Fetal death and malformations. *Neurology* **67**: 407-412, 2006.
64. Weinand ME, Hussain M, Labiner DM, Ahern GL. Correlation of electrocorticographic to clinical seizure onset and interhemispheric propagation times in temporal lobe epilepsy. *Pathophysiology* **13**: 233 – 236, 2006.
65. Atkinson PB, Labiner DM. Shocking the wandering nerve: vagus nerve stimulation after decade of widespread use. *Touch Briefings - US Neurological Disease* 2007, 1:44 – 46, 2007 <http://www.touchbriefings.com/cdps/cditem.cfm?nid=2785&cid=5>.
66. Labiner DM, Ahern GL. Vagus Nerve Stimulation (VNS) Therapy in Treatment-Resistant Depression: Therapeutic Parameter Settings. *Acta Neurologica Scandinavica*, **115**: 23 – 33, 2007.
67. Weinand ME, Farley C, Hussain N, Ahern GL, Labiner DM. Time from ictal subdural EEG seizure onset to clinical seizure onset: An electrocorticographic factor associated with temporal lobe epileptogenicity. *Neurological Research*, **29**: 862 – 870, 2007.
68. Antonucci SM, Beeson PB, Labiner DM, Rapsak, SZ. Lexical retrieval and semantic knowledge in patients with left inferior temporal lobe lesions. *Aphasiology* **22** (3) 281 - 304, 2007.
69. Berkovic SF and the Levetiracetam N01057Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy with tonic-clonic seizures. *Neurology*, **69**: 1751 - 1760, 2007.
70. Hayes SM, Melin JD, Dupuis M, Murray S, Labiner DM. Assessing the true learning needs of healthcare professionals in epilepsy care. *Epilepsy and Behavior* 11: 434 – 441, 2007.
71. Hoerth M, Draskowski J, Sirven J, Hinni M, Smith B, Labiner D. Improvement of vagus nerve stimulation-associated vocal cord paralysis with medialization thyroplasty. *Clinical Neurology and Neurosurgery* **109**: 788 - 790, 2007.
72. Glauser TA and the LEAD Group. Core elements of epilepsy diagnosis and management: consensus from the Leadership in Epilepsy, Advocacy and Development (LEAD) faculty. *Current Medical Research and Opinion* **24**: 3463 – 3477, 2008.
73. Thayer JF, Sollers JJ, Labiner DM, Weinand M, Herring AM, Lane RD, Ahern GL. Age related differences in prefrontal control of heart rate in humans: A pharmacological blockade study. *International Journal of Psychophysiology* **72**: 81-88, 2009.
74. Labiner DM, Ettinger AB, Fakhoury TA, et al. Effects of lamotrigine compared with levetiracetam on mood in a randomized, double-blind trial in patients with partial seizures. *Epilepsia* 50: 434 – 442, 2009.
75. Meador KJ and the NEAD Study Group. Neurodevelopmental effects of fetal antiepileptic drug exposure. *New England Journal of Medicine* **360**: 1597 – 1605, 2009.
76. Weinand M, Serxner B, Labiner D, Ahern G. Interhemispheric propagation time and temporal lobe epileptogenicity. *Pathophysiology* **16**: 39-42, 2009.

77. Meador KJ, Penovich P, Baker GA, et al. Antiepileptic drug use in women of childbearing age. *Epilepsy & Behavior*. 15: 339-43, 2009.
78. Gilliam F, Penovich P, Eagan C, et al. Conversations between community-based neurologists and patients with epilepsy: Results of an observational linguistic study. *Epilepsy & Behavior* **16**: 315–320, 2009.
79. Sankar R, Glauser TA, et al. Understanding therapeutic equivalence in epilepsy. *CNS Spectr*. **15**(2): 112-123, 2010.
80. Drake KW, Labiner DM. Lamotrigine: Once daily add-on therapy for epilepsy in adults experiencing partial onset seizures. *Clinical Medicine Reviews in Therapeutics*, 2010 <http://www.la-press.com/lamotrigine-once-daily-add-on-therapy-for-epilepsy-in-adults-experienc-a1892>.
81. Chong J, Kudrimoti HS, Lopez DCW, Labiner DM. Behavioral risk factors among Arizonans with epilepsy: Behavioral risk factor surveillance survey 2005/2006. *Epilepsy & Behavior* **17**: 511 – 519, 2010.
82. Labiner DM, Paradis PE, Duh MS, et al. Generic antiepileptic drugs and associated medical resource utilization in the United States. *Neurology* **74**:1566–1574, 2010.
83. Drake K, Labiner DM. Severe constipation associated with the use of rufinamide (Banzel) in an adolescent (letter). *Epilepsy & Behavior* **18**: 132, 2010.
84. Helmers SL, Paradis PE, Manjunath R, et al. Economic burden associated with the use of generic antiepileptic drugs in the United States. *Epilepsy & Behavior* **18**: 437-444, 2010.
85. Labiner DM and the Committee to Revise the Guidelines for Specialized Epilepsy Centers. Guidelines for essential services, personnel, and facilities in specialized epilepsy centers. *Epilepsia* **51**: 2322 - 2333, 2010.
86. Ouellette E, Chong J, Drake K, Labiner DM. Emergence department care of seizure patients: Demographic trends in southern Arizona. *Epilepsy & Behavior*, in press, 2011.
87. Thurman DJ, Beghi E, Begley CE, et al. Standards for epidemiologic studies and surveillance of epilepsy. *Epilepsia* **52** (suppl. 7): 1 – 26, 2011.
88. Helmers SL, Begnaud J, Cowley A, et al. Neurophysiology of vagus nerve stimulation: rational understanding of parameter settings. Submitted for publication, 2011.

## BOOK CHAPTERS:

1. Labiner DM, contributing author. In Schachter SC and Rowan J, *The Brainstorms Healer. Epilepsy in Our Experience*. Philadelphia: Lippincott-Raven Publishers, 1998.
2. Labiner DM, Kunkel-Thomas J, Anderson LR. Neurology in Native Americans. In Galloway JM, Goldberg BW, Alpert JA (eds.), *Clinical Medicine for Native Americans: Epidemiology, Pathology, Diagnosis and Therapy*. Boston: Butterworth Heinemann, 1999.
3. Labiner DM. Status epilepticus after a long day of white-water rafting in the Grand Canyon. In Schmidt D and Schachter S (eds.), *110 Cases of Epilepsy*. London: Martin Dunitz Publishers Ltd., 2001.
4. Foltz EJ, Labiner DM. The psychotropic effects of vagus nerve stimulation in epilepsy. In Kanner AM and Schachter SC (eds.), *Psychiatric Controversies in Epilepsy*. Amsterdam: Elsevier, 2008.
5. Kudrimoti H, Labiner DM. Epileptic drug treatment in special populations. In Wheless JW, Willmore LJ, Brumback RA (eds.), *Textbook of Epilepsy*, in press, 2008.

## EDUCATIONAL VIDEOS:

1. Ethics in Health Care. Produced by Medfilms, Inc., Tucson, Arizona, 1998. (Winner of 1999 Telly Award)

## EDITORIAL BOARD

*LEADing Issues in Epilepsy* (Quarterly Educational Journal published by Ortho-McNeil Neurologics)

## JOURNAL REVIEWER (*ad hoc*)

*Epilepsia*  
*Archives of Internal Medicine*  
*Journal of Clinical Psychiatry*  
*Geriatrics*  
*Journal of Neurotrauma*  
*Journal of Neurology*  
*Acta Neurologica Scandinavica*  
*Acta Neuropsychiatrica*  
*American Journal of Geriatric Pharmacotherapy*

MEDIA PRESENTATIONS (since 2000):

1. *Arizona Alumnus*, Winter 2000, Stimulating news!
2. *Telemundo* – Channel 40 TV, 21 February 2000, New treatments for epilepsy.
3. KNOT Radio Interview, 13 September 2000, Health Talk with Dr. Bruce Weary - Epilepsy (aired statewide)
4. *Arizona Illustrated*, 11 October 2000, Treating depression with the vagus nerve stimulator.
5. KVOA-4 TV News, 16 November 2000, Hidden signs of epilepsy in children.
6. *The Yuma Daily Sun*, 2 April 2001, Advances made in controlling seizures.
7. KVOA-4 TV News, 14 August 2001, Stem-cell research in neurology.
8. KUAT-KUAZ Radio, 22 October 2001, Cipro and seizures.
9. KXEW Radio, Interviewed on Live Program “Native Airways”, 18 November 2001, Epilepsy.
10. *Living with Epilepsy*, Fall/Winter 2002, What to expect from antiepileptic drugs.
11. KJLL Radio, 4 January 2003, Epilepsy.
12. *Arizona Daily Star*, 1 June 2003, David Labiner honored for commitment to camp.
13. *Arizona Daily Wildcat*, 10 October 2003, Neurologist wins national award.
14. *Arizona Daily Star*, 5 November 2003, He’s epilepsy’s No. 1 Arizona foe.
15. KVOA-4 TV News, 21 January 2005, Epilepsy and vaccinations.
16. *Neurology Today*, 21 February 2006, Quietly making a difference: Neurologists as unsung heroes.
17. *Vim & Vigor Magazine*, Summer 2007, Ceasing seizures.
18. *Epilepsy USA*, May/June 2007, Kids Speak Up! Children with epilepsy come to Capitol Hill to share their personal stories.
19. *Epilepsy Foundation - Empowerment Forum Press Conference*, 28 March 2008, Washington, D.C.
20. KVOA-4 TV News, 12 October 2008, Drivers with a History of Seizures.
21. KTVW-33 Univision News, 8 June 2010, Seniors, Seizures and Driving.
22. KUAZ Radio, Teacher’s Voices – The Science – Math Funfest, 20 August 2010
23. KGUN-9. The Morning Blend. Epilepsy in Seniors. 30 June 2011.

## LECTURES AND INVITED PRESENTATIONS (2005 - present):

1. Chair, Symposium on Treatment of Pharmaco-resistant epilepsy. Las Vegas, Nevada, 14 – 16 January 2005.
2. Chair, Symposium on Treatment of Pharmaco-resistant epilepsy. Las Vegas, Nevada, 18 – 20 February 2005.
3. Keynote Address. White-Coat Ceremony, College of Pharmacy, The University of Arizona, Tucson, Arizona, 22 April 2005.
4. Chair, Symposium on Refractory Epilepsy. Scottsdale, AZ, 13 – 14 May 2005.
5. Faculty, Epilepsy Empowerment Forum, Epilepsy Foundation (national) webcast. Scottsdale, Arizona, 21 May 2005.
6. Medical Staff Lecture. Anti-epileptic drug use in psychiatry. Cope Behavioral Health Services, Tucson, Arizona, 25 May 2005.
7. Faculty, Vagus Nerve Stimulation in Treatment Refractory Depression. Dallas, Texas, 3 – 4 June 2005.
8. Faculty, Mood Disorders in Epilepsy. San Francisco, California, 15 – 17 July 2005.
9. Medical Grand Rounds. Living with Epilepsy. Tucson Medical Center, Tucson, Arizona, 27 July 2005.
10. Neurology-Neurosurgery Grand Rounds. Epilepsy and Depression. Arizona Health Sciences Center, Tucson, Arizona, 29 July 2005.
11. Faculty and Chair, Mood Disorders in Epilepsy. Boston, Massachusetts, 12 – 14 August 2005.
12. Emergency Department Grand Rounds. The management of seizures in the emergency room. Arizona Health Sciences Center, Tucson, Arizona 16 August 2005.
13. Neurology Grand Rounds. Epilepsy and depression. Barrow Neurological Institute, Phoenix, Arizona, 26 August 2005.
14. Psychiatry Grand Rounds. Vagus nerve stimulation in depression. Arizona Health Sciences Center, Tucson, Arizona, 12 October 2005.
15. Course Director and Faculty, Eighteenth Annual Epilepsy Update. Westward Look Resort, Tucson, Arizona, 12 November 2005.
16. Faculty, Neuroepidemiology Special Interest Group, American Epilepsy Society Meeting, Washington, D.C., 3 December 2005.
17. Faculty, Neurostimulation Special Interest Group, American Epilepsy Society Meeting, Washington, D.C., 3 December 2005.
18. Neurology Grand Rounds. Epilepsy and depression. University of Southern California, Los Angeles, California, 20 December 2005.
19. Neurology Grand Rounds. Epilepsy and pregnancy: Picking the best medication. Tucson Medical Center, Tucson, Arizona, 8 February 2006.
20. Medical Staff Rounds. Diagnosing and treating epilepsy. Kayenta Indian Health Service Medical Center, Kayenta, Arizona, 24 April 2006.
21. Medical Staff Rounds. Diagnosing and treating epilepsy. Chinle Indian Health Service Medical Center, Chinle, Arizona, 25 April 2006.
22. Medical Staff Rounds. Diagnosing and treating epilepsy. Tuba City Indian Health Service Medical Center, Tuba City, Arizona, 27 April 2006.
23. Neurology-Neurosurgery Grand Rounds. Epilepsy, Pregnancy and the Child. Arizona Health Sciences Center, Tucson, Arizona, 25 August 2006.
24. Faculty, Understanding the Dimensions of Epilepsy: considerations for comprehensive management. Chicago, Illinois, 15 – 17 September 2006.
25. Faculty, Nineteenth Annual Epilepsy Update. Mayo Clinic, Scottsdale, Arizona, 3 – 4 November 2006.

26. Faculty, Epilepsy Symposium. Epilepsy Today: Your options, your choices. Epilepsy Foundation of Arizona, Scottsdale, Arizona, 4 November 2006.
27. Faculty and Co-Chair, Legal Aspects of Epilepsy Care. American Epilepsy Society Meeting, San Diego, California, 4 December 2006.
28. Faculty, Epilepsy Symposium. Comprehensive Review of Epilepsy Management. American Epilepsy Society Regional Meeting, Los Angeles California, 24 March 2007.
29. Faculty, Sixteenth Annual Southwestern Conference on Medicine. Epilepsy, Pregnancy and the Child. Tucson, Arizona, 30 March 2007.
30. Faculty, International Course on the Treatment of Pharmacoresistant Epilepsy, Vagus Nerve Stimulation for Treatment Resistant Epilepsy, Instituto Mexicano del Seguro Social, Mexico City, 15 June 2007.
31. Faculty, Arizona Neurological Society 2007 CME Conference, The Effective Use of Antiepileptic Medications, Sedona, Arizona, 4 August 2007
32. Faculty, Twentieth Annual Epilepsy Update. Problems and Solutions for Epilepsy Management. Barrow Neurological Institute, Phoenix, Arizona, 3 November 2007.
33. Faculty, Epilepsy Symposium. Living Well with Epilepsy. Epilepsy Foundation of Arizona, Phoenix, Arizona, 3 November 2007.
34. Neurology-Neurosurgery Grand Rounds. Effective Use of Medications in Treating Epilepsy. Arizona Health Sciences Center, Tucson, Arizona, 25 January 2008.
35. Faculty, Effective Use of Medication in Treating Epilepsy. College of Psychiatric and Neurologic Pharmacists Annual Meeting. Scottsdale, Arizona, 14 April 2008.
36. Neurology-Neurosurgery Grand Rounds. The Genetics of Epilepsy. Arizona Health Sciences Center, Tucson, Arizona, 15 August 2008.
37. Course Director and Faculty, 21st Annual Epilepsy Update. The University of Arizona, Tucson, Arizona, 8 November 2008.
38. Emergency Medicine Grand Rounds. Emergency management of seizures and epilepsy. Arizona Health Sciences Center, Tucson Arizona, 21 April 2009.
39. Faculty, American Society of Electroneurodiagnostic Technologists 50<sup>th</sup> Anniversary Meeting, Phoenix, Arizona, 8 August 2009.
40. Neurology/Neurosurgery Grand Rounds. Generic substitution of antiepileptic medications. Arizona Health Sciences Center, Tucson Arizona, 21 August 2009.
41. Faculty, Neurology Residents Scholar Program. Chandler, Arizona, 4 – 7 September 2009.
42. Faculty, Penry Neurostimulation Fellowship. Wake Forest University, Winston – Salem, North Carolina, 11 – 13 September 2009.
43. Frontiers in Medical Research Seminars. The prevalence of epilepsy along the Arizona – Mexico border. Arizona Health Sciences Center, Tucson Arizona, 6 April 2010.
44. Neurosciences Grand Rounds. Generic substitution of antiepileptic medications: Is bioequivalence really the same? University of California, San Diego, 9 April 2010.
45. Faculty, Penry Neurostimulation Fellowship. Wake Forest University, Winston – Salem, North Carolina, 3 - 5 September 2010.
46. Faculty, Neurology Residents Scholar Program. Chandler, Arizona, 23 - 26 September 2010.
47. Faculty, Congresso Centroamericano de Neurologia. San Jose, Costa Rica, 25 – 27 November 2010.
48. Faculty, Epidemiology Special Interest Group, Annual Meeting of the American Epilepsy Society, San Antonio, Texas, 3 – 7 December 2010.
49. Co-Chair, Hot Topics Symposium on Healthcare Reform and Military Head Injuries and Epilepsy. Annual Meeting of the American Epilepsy Society, San Antonio, Texas, 3 – 7 December 2010.



50. Faculty – Visiting Professor. Generic substitution of antiepileptic medications: Is bioequivalence really the same? Mayo Clinic – Arizona, 23 March 2011.
51. Speaker and Panel Member. Epilepsy education of neurologists. Workshop on Public Health Dimensions of the Epilepsies. Institute of Medicine of The National Academies. Washington, D.C. 28 – 29 June 2011.
52. Speaker and Planning Committee. Southwest Summer CME Conference, Arizona Neurological Society. The Latest Epilepsy Research. Sedona, Arizona 29 – 31 July 2011.

#### GRANTS AND CONTRACTS:

1. Abbott Laboratories, Protocol # M88-194, Depakote in the Treatment of Complex Partial Seizures, Co-Investigator
2. R.W. Johnson Pharmaceutical Research Institute, Protocols YF and YG, A Double-Blind, Placebo-Controlled, Parallel, Efficacy and Safety Study of Topiramate in Patients with Partial Epilepsy, Co-Investigator
3. Abbott Laboratories (Parexel International Corp.), Protocol M90-540, The Safety of Intravenous Valproate, Principal Investigator
4. Abbott Laboratories, Protocol # M91-605, Safety and Efficacy of bid and qid Dosing with Tiagabine HCl Versus Placebo as Adjunctive Treatment for Complex Partial Seizures, Principal Investigator
5. National Institutes of Health - National Institute of Neurological Disorders and Stroke, MAA/RFP NIH-NINDS-91-10, Master Agreement for the Clinical Evaluation of Investigational Antiepileptic Drugs, Principal Investigator
6. Professional Postgraduate Services, Quality of Life in Epilepsy Inventory Validation Principal Investigator
7. Epilepsy Foundation of America, Epilepsy in the Tohono O'odham Nation, Principal Investigator
8. McRae Family Foundation, Neurochemical studies in Human Epilepsy, Principal Investigator
9. Burroughs-Wellcome, Protocol # 26, A Protocol to Provide Lamictal for the Treatment of Serious or Life-Threatening Epilepsy, Co-Investigator
10. Dr. Willmar Schwabe GMGH & Company, Protocol # LSG-1, A Randomized Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Losigamone in Patients with Inadequately Controlled Partial Seizures, Principal Investigator
11. Cyberonics, Protocol # E05, Assessment of Vagus Nerve Stimulation for Adjunctive Treatment of Epilepsy Patients who have Refractory Partial Onset Seizures with Alteration of Consciousness, Principal Investigator
12. Cambridge Neuroscience, Inc., Protocol # CNS 1102-012, Efficacy and Safety of Cerestat (Aptiganel HCl) as a Neuroprotective Following Severe Traumatic Brain Injury, Principal Investigator
13. Sugan, Inc., Protocol 101.015, A Phase III Randomized Study of SU101 versus Procarbazine for Patients with Glioblastoma Multiforme in First Relapse, Principal Investigator
14. Astra Merck, Protocol 164, An Inpatient, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of Remacemide Hydrochloride as Monotherapy in Subjects with Partial-Onset Seizures, Principal Investigator
15. Astra Merck, Protocol 199, A Long-Term Open-Label Safety Study of Remacemide Hydrochloride in Subjects with Epilepsy, Principal Investigator

16. Novartis, Protocol 3310101016, A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Stratified, Parallel-Group Trial of Rufinimide as Adjunctive Therapy in Children and Adults with Inadequately Controlled Partial Seizures, Principal Investigator
17. Abbott Laboratories, Protocol M98-938, The Safety and Tolerance of Intravenous Depacon at an Infusion Rate up to 3.0 mg/kg/minute in Subjects with Epilepsy, Principal Investigator
18. Parke-Davis, Protocol 1008-034, Pregabalin, A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study in Patients with Partial Seizures, Principal Investigator
19. Parke-Davis, Protocol 1008-035, Pregabalin: A Open-Label, Multicenter Follow-On Study to Determine Safety and Efficacy in Patients with Partial Seizures, Principal Investigator
20. Novartis, Protocol CRUF331-0039, A Multicenter, Double-Blind, Randomized, Placebo-Control, Parallel-Group, Monotherapy Study of Rufinamide in Patients with Recent-Onset Partial Seizures, Principal Investigator
21. Cyberonics, Protocol D02, A Multicenter, Pivotal, Safety and Efficacy Study of the NeuroCybernetic Prosthesis (NCP) System in Patients with Depression, Co-Principal Investigator (with Francisco Moreno, M.D.)
22. Novartis, Protocol US01 (STOPS Trial), Safety and Therapeutic Effect of Oxcarbazepine in Patients with Partial Seizures, Principal Investigator
23. UCB Pharma, Protocol RPCE00A1201/Study N01030, A Phase IV, Open-Label, Multi-Center Community-Based Trial Studying the Safety and Efficacy of Levetiracetam as add-on Therapy in Adult Patients with Treatment-Resistant, Partial-Onset Epilepsy, Co-Principal Investigator (with Scott Sherman, M.D.)
24. Neurodevelopment Effects of Antiepileptic Drugs (subinvestigator)  
Sponsor: NIH with funds administered through Georgetown University Hospital (Principal Investigator – Kimford Meador, M.D.)
25. GlaxoSmithKline, Protocol LAM-40117, A Multicenter, Open-Label, Pilot Study of Lamotrigine as Adjunctive Therapy and Monotherapy in Patients with Epilepsy and Comorbid-Depressive Symptoms, Principal Investigator
26. GlaxoSmithKline, Protocol LAM-40124, An Assessment of Behavioral Changes Associated with Lamotrigine and Levetiracetam in Patients with Epilepsy, Principal Investigator **(Developed protocol)**.
27. Ortho-McNeil, Protocol CAPSS-272, A Double-Blind Trial Comparing the Efficacy, Tolerability and Safety of Monotherapy Topiramate versus Phenytoin in Subjects with Seizures Indicative of New Onset Epilepsy, Principal Investigator
28. Eisai, Protocol E2007-A001-206, A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 Given as Adjunctive Therapy in Patients with Refractory Partial Seizures, Principal Investigator
29. Centers for Disease Control and Prevention. Prevalence of Epilepsy along the Arizona – Mexico Border (MM-0953-06/06). Principal Investigator (30% effort)
30. GlaxoSmithKline, Protocol RM2005-00506, A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures.
31. Johnson & Johnson, Protocol CARISEPY3013/3014, A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures, Followed by an Open-Label Extension Study.
32. Johnson & Johnson, Protocols 333369EPY3001 (Double-Blind) and 333369EPY3004 (Open-Label), A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RWJ-333369 as

Adjunctive Therapy in Subjects with Partial Onset Seizures Followed by an Open-Label Extension Study.

33. Eisai, Protocol E2007-G000-305, A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures.
34. Eisai, Protocol E2007-G000-307, A 14-Month Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures.
35. UCB, Inc., Protocol N01199, An Open-Label, Multicenter, Follow-up Trial to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 15 mg/day in Subjects Aged 16 Years or Older Suffering from Epilepsy.
36. Ortho-McNeil, Protocol CARISEPY3007, A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in Subjects with Partial Onset Seizures.
37. Eisai, Inc., Protocol E2080-A001-302, An Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures.
38. UCB, Inc., Protocol N01253, An International, Double-Blind, Parallel-Group, Placebo-Controlled, Randomized Study: Evaluation of the Efficacy and safety of Brivaracetam in Subjects (> 16 to 70 years old) with Partial Onset Seizures.
39. Eisai, Inc., Protocol E2080-A001-301, A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide given as Adjunctive Therapy in Patients with Refractory Partial Seizures.
40. King Pharmaceuticals, Protocol K826-05-3001/02: 3/20/06, A Phase 3, Randomized, Double-Blind, Parallel, Placebo-Controlled, Multicenter Study, with Optional Open-Label Continuation, of the Efficacy and Safety of Vanquix Auto-Injector (Diazepam Injection) for the Management of Selected, Refractory, Patients with Epilepsy who Require Intermittent Medical Intervention to Control Episodes of Acute Repetitive Seizures.

## ABSTRACTS

1. Smith DB, Sidman RD, Henke JS, Weitz F, Kearfott B, Labiner DM. Detection of focal cortical dysfunction using the visual evoked response. Presented at the Second Annual International Evoked Potential Symposium, 18 – 20 October 1982, Cleveland, Ohio
2. Smith DB, Sidman RD, Henke JS, Flanigin HF, Evans CN, Labiner DM. Validation of a computer method for localizing EEG potentials. Presented at the Southern EEG Society Meeting, 29-31 October 1982, Williamsburg, Virginia
3. Smith DB, Sidman RD, Henke JS, Flanigin HF, Evans CN, Labiner DM. A reliable method for localizing both depth and superficially generated EEG potentials. *Neurology* **33** (Suppl 2): 70, 1983
4. Smith DB, Henke JS, Sidman RD, Flanigin HF, Labiner DM. Validation of a noninvasive method for localizing intracranial sources of EEG. *Neurology* **34** (Suppl 1): 124, 1984
5. Ng SKC, Labiner DM, Hauser WA, Brust JCM, Healton EB. Neurological deficits and adult-onset seizures. *Neurology* **37** (Suppl 1): 323, 1987
6. Labiner DM, Ng SKC, Hauser WA, Brust JCM. Cerebellar dysfunction increases risk for seizures. *Epilepsia* **28**: 634, 1987
7. Sorock GS, Labiner DM, Hauser WA. Peripheral nerve dysfunction and the risk of falls in the elderly. *American Journal of Epidemiology* **130**: 817-818, 1989
8. Labiner DM, Hosford DA, Shin C, McNamara JO. N-methyl-D-aspartate channel blockers inhibit seizure induced rise in *c-fos* mRNA in hippocampus of kindled rats. *Society of Neuroscience Abstracts* **15** (1): 841, 1989
9. Simonato MG, Hosford DA, Labiner DM, Shin C, McNamara JO. Early gene expression in the hippocampus in the kindling model. *Society of Neuroscience Abstracts* **15** (1): 841, 1989
10. Labiner DM, Hosford DA, Shin C, McNamara JO. An N-methyl-D-aspartate channel blocker, MK-801, inhibits seizure induced rise in *c-fos* mRNA in hippocampus of kindled rats. *Epilepsia* **30**: 697, 1989
11. Shin C, Labiner DM, Hosford DA, McNamara JO. N-methyl-D-aspartate (NMDA) receptor activation is required for full expression of *c-fos* mRNA induced by kindled seizures. *Neurology* **40** (Suppl 1): 211, 1990
12. Labiner DM, Hosford DA, Shin C, Cao Z, Butler L, McNamara JO. Dissociation of neuronal activity and seizure-induced *c-fos* mRNA expression by NMDA receptor antagonist. *Society of Neuroscience Abstracts* **16** (1): 848, 1990
13. Oommen KJ, Patton D, Fenstermacher W, Seeger J, Carter LP, Weinand ME, Labiner DM, Ahern G, Herring A, Tackenberg J, Martynec C. Comparison of SPECT and MRI foci to EEG foci in patients with complex partial seizures. *Neurology* **42** (Suppl 3): 157, 1992
14. Weinand ME, Carter LP, Oommen KJ, Labiner DM, Patton D, Orozco J, Ahern G, Herring A. Surface monitoring of cerebral cortical blood flow in epilepsy. *Neurology* **42** (Suppl 3): 158, 1992
15. Labiner DM, Weinand ME, Ahern GL, Oommen KJ, Carter LP, Patton D, Herring A. Concordance between noninvasive and invasive evaluation techniques in seizure focus localization. *Epilepsia* **33** (Suppl 3): 91, 1992
16. Weinand ME, Wyler AR, Carter LP, Oommen KJ, Labiner DM, Ahern GL, Hermann B, Herring A. Long-term subdural strip electrocorticographic monitoring of ictal *deja vu*. *Epilepsia* **33** (Suppl 3): 95, 1992
17. Huxtable RJ, Lieu PL, Weinand ME, Labiner DM. Decreased synaptosomal taurine and glutamine concentrations in focal as compared to nonfocal temporal lobe tissue biopsied from patients with intractable complex partial seizures. Presented at the International Symposium on Taurine in Health and Disease, 29 August - 1 September 1993, Cologne, Germany

18. Labiner DM, Lieu PL, Weinand ME, Huxtable RJ. Neuroactive amino acids in synaptosomes from focal and nonfocal temporal lobe tissue biopsied from patients with intractable complex partial seizures. *Society of Neuroscience Abstracts* **16** (2): 1028, 1993
19. Sachdeo RC and the M91-605 Investigators. Safety and efficacy of bid and qid dosing with tiagabine HCl versus placebo as adjunctive treatment for partial seizures. *Epilepsia* **34** (Suppl 6): 36, 1993
20. Hutzler R, Oommen KJ, Ahern GL, Weinand ME, Carter LP, Labiner DM, Talwar D. Cerebral blood flow during hyperventilation in epileptic and nonepileptic temporal cortex. *Epilepsia* **34** (Suppl 6): 77, 1993
21. Weinand ME, Carter LP, Oommen KJ, Labiner DM, Talwar D, Orozco JA. Long-term surface cortical cerebral blood flow monitoring in temporal lobe epilepsy. *Epilepsia* **34** (Suppl 6): 97, 1993
22. Labiner DM, Lieu PL, Weinand ME, Huxtable RJ. Alterations in neuroactive amino acids in synaptosomes isolated from both focal and nonfocal temporal lobe of individuals with medically intractable epilepsy. *Epilepsia* **34** (Suppl 6): 126, 1993
23. Ahern GL, Herring AM, Tackenberg JN, Schwartz GE, Seeger JF, Labiner DM, Weinand ME, Oommen KJ. Affective self-report during the intracarotid sodium amobarbital test. Presented at the International Neuropsychological Society Meeting, 2-5 February 1994, Cincinnati, Ohio
24. Labiner DM, Ahern GL, Kolb MA, Johnson DS, Vengrow MI. Gabapentin is both safe and effective in treating seizures associated with porphyria. *Epilepsia* **35** (Suppl 8): 53, 1994
25. Talwar D, Weinand ME, Baldwin MA, Labiner DM, Griesemer DA, Oommen KJ. Surgical treatment of intractable symptomatic occipital epilepsy. *Epilepsia* **35** (Suppl 8): 69, 1994
26. Weinand ME, Labiner DM, Oommen KJ, Talwar D. Subdural strip monitoring and surgical decision making in refractory epilepsy. *Epilepsia* **35** (Suppl 8): 71, 1994
27. Weinand ME, Carter LP, Oommen KJ, Hutzler R, Labiner DM, Talwar D, El-Saadany WF, Ahern GL. Response of human epileptic temporal lobe cortical blood flow to hyperventilation. *Epilepsia* **36** (Suppl 4): 141, 1995
28. Labiner DM, McGregor T, Ahern GL, Bell S. The cost of epilepsy in Yuma County, Arizona. *Epilepsia* **36** (Suppl 4): 95, 1995
29. Weinand ME, El-Saadany WF, Labiner DM, Talwar D, Ahern GL. Subdural strip electrode monitoring and surgical decision making in refractory epilepsy: Validity and prognostic value of noninvasive localizing data. Presented at the 41<sup>st</sup> Annual Meeting of the Western Neurosurgical Society, Gleneden Beach, Oregon, 9 – 12 September 1995.
30. Weinand ME, El-Saadany WF, Sioutos PJ, Carter LP, Labiner DM, Oommen KJ. Vascular steal theory of epileptogenicity. Presented at the 46<sup>th</sup> Annual Meeting of Congress of Neurological Surgeons, Montreal, Quebec, Canada, 28 September - 3 October 1996
31. Weinand ME, Carter LP, El-Saadany WF, Sioutos PJ, Labiner DM, Oommen KJ. Cerebral blood flow and temporal lobe epileptogenicity. *Epilepsia* **37** (Suppl 4): 89, 1996
32. Ahern GL, Herring AM, Labiner DM, Weinand ME. Quantification of hemispatial neglect during the intracarotid amytal procedure. Presented at the 25<sup>th</sup> Annual Meeting, International Neuropsychological Society, Orlando, Florida, 5-8 February 1997
33. Labiner DM, McGregor T, Ahern GL, Bell S. The cost of epilepsy in Yuma County, Arizona. *Epilepsia* **38** (Suppl 3): 95, 1997
34. Labiner DM, Yan CC, Weinand ME, Huxtable RJ. Disturbances of amino acids from temporal lobe synaptosomes in human complex partial epilepsy. Presented at the International Taurine Symposium, Tucson, Arizona, 15 - 19 July 1997
35. Labiner DM. Results from long-term safety and efficacy monitoring. Presented at the North American Vagus Nerve Stimulation Symposium, Colorado Springs, Colorado, 17 - 20 August 1997

36. Labiner DM, Ahern GL. A meta-analysis of vagus nerve stimulation in treating medically refractory epilepsy. *Epilepsia* **38** (Suppl 8): 109, 1997
37. DeGiorgio C et al. Multicenter, double-blind controlled trial of vagus nerve stimulation (NCP system) for medically intractable partial-onset seizures: initial report of the United States E05 study group. *Epilepsia* **38** (Suppl 8): 133, 1997
38. Reminger SL, Herring AM, Ahern GL, Weinand ME, Labiner DM. The utility of neuropsychological test measures in the prediction of seizure lateralization in temporal lobe epilepsy. Presented at the 26<sup>th</sup> Annual International Neuropsychological Society, Honolulu, Hawaii, February 1998
39. Griffiths RI, Schrammel PN, Morris GL, Wills SH, Labiner DM, Strauss MJ. Payor costs of patients diagnosed with epilepsy. *Epilepsia* **39** (Suppl 6): 225, 1998.
40. DeGiorgio CM and the E05 Study Group. Multicenter double-blind crossover and 6-month follow-up study of vagus nerve stimulation for intractable partial seizures. *Epilepsia* **39** (Suppl 6): 69, 1998.
41. Sirven JI and the VNS Study Group. Vagus nerve stimulation therapy for epilepsy in adults 50 years and older: A multicenter study. *Neurology* **52** (Suppl 2): A110, 1999.
42. DeGiorgio C and the VNS Study Group. Multicenter long-term efficacy and safety study of vagus nerve stimulation for intractable partial seizures. *Neurology* **52** (Suppl 2): A111, 1999.
43. Morris GL and the VNS Study Group. Seizure freedom analysis on 195 refractory epilepsy patients receiving vagus nerve stimulation therapy. *Neurology* **52** (Suppl 2): A239, 1999.
44. Weinand ME, Deogaonkar M, Kester M, Labiner DM. Time from electrocorticographic to - clinical seizure onset: Prognostic value for selecting temporal lobectomy candidates. *Epilepsia* **40** (Suppl 2): 29, 1999.
45. Deogaonkar M, Weinand ME, Labiner DM. Non-invasive versus invasive focus localization in surgical decision making in epilepsy surgery. *Epilepsia* **40** (Suppl 2): 83, 1999.
46. Deogaonkar M, Weinand ME, Labiner DM. Role of invasive monitoring in surgical decision making in epilepsy surgery. *Neurosurgery* **45**: 699, 1999.
47. Drazkowski JF, Fisher RS, Blum DE, Labiner DM. Driving crashes in Arizona after reducing the required seizure-free interval. *Epilepsia* **40** (Suppl 7): 104, 1999.
48. Labiner DM, Schwirtz D, Ahern G, MacDonald J, Weinand ME. Shorter pulse width of vagus nerve stimulation is as effective in reducing seizure frequency as standard stimulation and is better tolerated. *Epilepsia* **40** (Suppl 7): 141, 1999.
49. Cantrell D and the Depakote Study Team. Rapid infusions of valproate sodium injection (Depacon) are safe and well tolerated. Presented at the American Epilepsy Society Annual Meeting, Los Angeles, California, December 1 – 6, 2000.
50. Meador KJ and NEAD Study Group. Antiepileptic Drugs in Pregnancy: Differences in U.K. and U.S.A. *Epilepsia*, 2003;44 (Suppl. 9):289.
51. Meador KJ and NEAD Study Group. Antiepileptic Drugs in Pregnancy. *Neurology* 2004;62 (Suppl 5):A311.
52. Meador KJ and NEAD Study Group. Differential Effects of Antiepileptic Drugs on Serious Adverse Outcomes in Children Exposed In Utero. *Epilepsia* 2004;45 (Suppl 3):58.
53. Meador KM, Loring DW, Baker G, Smith JC, Pennell P, Liporace J, Kalayjian L, Kini U, NEAD Study Group. Differential and dose dependent effects of in utero antiepileptic drugs. *Neurology* 2005;64 (Suppl 1):A427
54. Antonucci SM, Beeson PM, Labiner DM, Rapcsak SZ. The role of the left inferior temporal lobe in naming and semantic knowledge. Presentation at the Annual Meeting of the International Neuropsychological Society. Boston, Massachusetts, February 2006.

55. Hayes SM, Labiner DM, Murray S. Remaining current on the continuing medical education literature. Presentation at the Annual Meeting of the Alliance of Continuing Medical Education. Phoenix, Arizona, 18 January 2007.
56. Melin JD, Hayes SM, Labiner DM. Behavioral needs assessment: *how do you truly find out what they don't know that they don't know?* Presentation at the Annual Meeting of the Alliance of Continuing Medical Education. Phoenix, Arizona, 18 January 2007.
57. Labiner DM, Chong J. Prevalence of epilepsy along the Arizona – Mexico border. Presentation at the Seventh Annual Border Health Conference, Rio Rico, Arizona, 16 April 2007.
58. Labiner DM. Advocacy for individuals with epilepsy. Presentation at the Public Policy Institute, Epilepsy Foundation, Washington, D.C, 23 April 2007.
59. Hayes SM, Melin JD, Labiner DM. If you have no patients, how do you get outcome data? Presentation at the Annual Meeting of the Alliance of Continuing Medical Education. Orlando, Florida, 19 - 22 January 2008.
60. Atkinson PB, Chong J, Nguyen J, Labiner DM. The effect of depression on epilepsy self-efficacy in Hispanics. (abstract 1.071). Presented at the Annual Meeting of the American Epilepsy Society, Seattle, Washington, 5 – 9 December 2008.
61. Penovich P, et al. Discussions of side effects and mood with patients with epilepsy: Results of an observational linguistic study (abstract 1.369). Presented at the Annual Meeting of the American Epilepsy Society, Seattle, Washington, 5 – 9 December 2008.
62. Chong J, Labiner DM. Prevalence of epilepsy along the Arizona – Mexico border (abstract 2.165). Presented at the Annual Meeting of the American Epilepsy Society, Seattle, Washington, 5 – 9 December 2008.
63. Labiner DM, et al. Impact of Generic Substitution of Antiepileptic Drugs on Medical Resource Utilization in the United States (abstract 3.223). Presented at the Annual Meeting of the American Epilepsy Society, Seattle, Washington, 5 – 9 December 2008.
64. Stern J, et al. Improving neurologist-patient communication to promote more effective assessment of side effects and comorbidities in epilepsy: Results of a phase II communication study (abstract 1.329). Presented at the Annual Meeting of the American Epilepsy Society, Boston, Massachusetts, 4 – 8 December 2009.
65. Chong J, et al. Relationships between depression, epilepsy self-efficacy, and stigma in Hispanics (abstract 2.261). Presented at the Annual Meeting of the American Epilepsy Society, Boston, Massachusetts, 4 – 8 December 2009.
66. Labiner DM, Chong J. Undercounting epilepsy: Finding the undiagnosed along the Arizona – Mexico border (Abstract 3.209). Presented at the Annual Meeting of the American Epilepsy Society, Boston, Massachusetts, 4 – 8 December 2009.
67. Stern J, et al. Neurologist-patient dialogue about mood/behavior and adverse effects of antiepileptic drugs: results of a phase II communication study. *Neurology* 74(suppl 2): A303.